21.62
전일 마감가:
$22.07
열려 있는:
$21.84
하루 거래량:
157.91K
Relative Volume:
0.36
시가총액:
$800.90M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.84%
1개월 성능:
+1.55%
6개월 성능:
+42.96%
1년 성능:
-4.38%
Ceribell Inc Stock (CBLL) Company Profile
명칭
Ceribell Inc
전화
(800) 436-0826
주소
360 N. PASTORIA AVENUE, SUNNYVALE
CBLL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
CBLL
Ceribell Inc
|
21.59 | 818.70M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
107.33 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.29 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.75 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.37 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.70 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Raymond James | Strong Buy |
| 2025-06-24 | 개시 | BTIG Research | Buy |
| 2025-04-04 | 개시 | Ladenburg Thalmann | Buy |
| 2024-11-05 | 개시 | BofA Securities | Buy |
| 2024-11-05 | 개시 | Canaccord Genuity | Buy |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
모두보기
Ceribell Inc 주식(CBLL)의 최신 뉴스
Income Plays: Is CeriBell Inc a top pick in the sectorWeekly Loss Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Fed Meeting: What are the risks of holding CeriBell Inc2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
What’s the profit margin of CeriBell Inc.Analyst Upgrade & Safe Entry Trade Reports - mfd.ru
CeriBell, Inc. $CBLL Shares Acquired by Emerald Mutual Fund Advisers Trust - MarketBeat
Ceribell director resigns to pursue other professional ventures - MSN
Targets Report: Is Bolt Projects Holdings Inc stock a buy or sellPortfolio Return Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Josef Parvizi Sells 25,000 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Ceribell director Parvizi sells $573k in shares - Investing.com
Ceribell director Parvizi sells $573k in shares By Investing.com - Investing.com UK
CeriBell a new buy at BTIG on growth in EEG monitoring system - MSN
FDA clearances: Siemens Healthineers, Medtronic, CeriBell - Modern Healthcare News
Risk Hedge: Does CeriBell Inc stock reflect fundamentalsJuly 2025 Levels & Daily Chart Pattern Signal Reports - baoquankhu1.vn
CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion - Yahoo Finance
Growth Value: Does CeriBell Inc have consistent dividend growthAnalyst Downgrade & Real-Time Market Trend Scan - baoquankhu1.vn
Protara, Ceribell rise on FDA breakthrough designations - MSN
CBLL: FDA-cleared AI neuromonitoring expands to pediatrics and delirium, driving growth and efficiency - TradingView
CBLL: 2026 growth will accelerate with new FDA clearances, VA expansion, and pediatric launches - TradingView — Track All Markets
Ceribell sues Natus Medical for patent infringement - MSN
CeriBell, Inc. (NASDAQ:CBLL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Ceribell shares advance after FDA grants breakthrough device status - MSN
CeriBell, Inc.'s (NASDAQ:CBLL) Shares May Have Run Too Fast Too Soon - simplywall.st
Is CeriBell Inc. stock a buy on dips2025 Top Decliners & Long-Term Safe Return Strategies - Улправда
Is CeriBell Inc. stock attractive for retirement portfoliosOptions Play & AI Driven Price Predictions - ulpravda.ru
Will CeriBell Inc. stock rally after Fed decisions2025 Key Highlights & Reliable Intraday Trade Plans - ulpravda.ru
Aug Technicals: Why CeriBell Inc. stock could outperform in 2025Portfolio Risk Summary & High Return Trade Opportunity Guides - ulpravda.ru
Ceribell’s Foehr sells $125k in shares after option exercise By Investing.com - Investing.com India
CeriBell (NASDAQ:CBLL) VP David Foehr Sells 5,556 Shares - MarketBeat
Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Ceribell CEO Chao Xingjuan sells $1.68 million in shares By Investing.com - Investing.com South Africa
Ceribell CEO Chao Xingjuan sells $1.68 million in shares - Investing.com
Pittsburgh Post-GazetteCeriBell, Inc.Common Stock (Nasdaq:CBLL) Detailed Stock Data - FinancialContent
Will CeriBell Inc. stock benefit from infrastructure spendingFootwear buying guidance for recovery days and low impact training focuses on balanced cushioning and support, making it a solid option for daily use. - ulpravda.ru
Ceribell Gets FDA Breakthrough Device Status - Medical Device and Diagnostic industry
Ceribell’s AI Stroke Detection Tool Gains FDA Breakthrough Status - Zenopa
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection - Yahoo Finance
FDA grants breakthrough designation for Ceribell’s stroke detection monitor By Investing.com - Investing.com Nigeria
Ceribell receives FDA breakthrough device designation for LVO SD monitor - TipRanks
CeriBell (NASDAQ:CBLL) Hits New 12-Month HighHere's Why - MarketBeat
Ceribell Wins FDA Breakthrough Status for LVO Stroke Tool - TipRanks
Ceribell, Inc. Receives FDA Breakthrough Device Designation for LVO Stroke Solution - TradingView — Track All Markets
Protara, CeriBell rise on FDA breakthrough designations (TARA:NASDAQ) - Seeking Alpha
Ceribell receives FDA breakthrough device designation for LVO stroke detection - marketscreener.com
Ceribell’s LVO Stroke Detection Monitor Wins FDA Breakthrough Nod - Medical Product Outsourcing
CeriBell stock climbs after FDA Breakthrough Device Designation By Investing.com - Investing.com Nigeria
CeriBell stock climbs after FDA Breakthrough Device Designation - Investing.com India
FDA grants breakthrough designation for Ceribell’s stroke detection monitor - Investing.com India
Ceribell Inc (CBLL) 재무 분석
Ceribell Inc (CBLL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):